Cephalon news from FiercePharma
NewsPublic Citizen joins FDA review
When Cephalon asked the FDA to expand the use of its opioid painkiller Fentora, did it see the shape of things to come at the Read more...
FDA panel rejects broader Fentora use
No go, Fentora. An FDA advisory panel voted against broadening the use of Cephalon's painkiller, Read more...
Expert panel to mull broader Fentora use
Everyone suddenly has an opinion on Fentora. Good opinion: The Cephalon painkiller got European approval a couple of weeks ago, after two years on the market in the U.S. Another good opinion, in the Read more...
Cephalon pays CEO more than hefty rivals
Which drug exec gets paid 140 percent more than the median among his peers? Hint: His company makes the anti-narcolepsy med Read more...
FTC sues Cephalon for blocking generics
Here's one way generics might pay off. The feds are accusing Cephalon of bribing drugmakers to keep copycat Provigil off the market. According to an FTC lawsuit against the company, Cephalon paid Read more...
ALSO NOTED: Nigeria wants to extradite U.S. Pfizerites; PDI BioPharma sells cardio drugs;
> Just weeks after Nigerian officials sent local Pfizer officials scurrying to avoid arrest, the Kano state government is asking that three Americans be extradited and tried in the ongoing court Read more...
ALSO NOTED: Sepracor chair to retire in May; Study shows Glaxo drug outpacing Pfizer's Spiriva;
> Sepracor chairman Timothy Barberich will retire by May, according to a disclosure filed with the Securities and Exchange commission; Barberich is the drug maker's former CEO. Read more...
10. Fentora - Top 10 Warnings and Recalls
Drug: Fentora 2006 sales: $370 million Manufacturer: Cephalon Safety concern: Warning; improper dosing leading to death Related Articles: > New warning for off-label Fentora. Read more...
6. Provigil - Top 10 Warnings and Recalls
Drug: Provigil 2006 sales: $727 million Manufacturer: Cephalon Safety concern: Warning; Stevens-Johnson syndrome, psychiatric problems Related Articles: > FDA warns of Provigil risks. Read more...
New drug warnings poised for rollout
New warnings and warning recommendations are flying out of the FDA this week like geese flying south for the winter, partly because of an FDA advisory panel is meeting. Here's the latest:Committee Read more...
| Press ReleasesPRESS RELEASE: Cephalon Announces Strong Third Quarter Financial Results Cephalon Announces Strong Third Quarter Financial Results Company Also Announces Agreement in Principle with U.S. Attorney's Office; Earnings Exceed Company Guidance; Company Again Increases 2007 Read more... PRESS RELEASE: Cephalon Announces Positive Treanda Trial Results Cephalon Announces Positive Treanda Trial Results FRAZER, Pa., Oct. 23 -- Cephalon today announced positive results from a Phase 3 clinical trial of TREANDA® (bendamustine HCl) in patients with Read more... FDA WARNING: FDA Warns of Potential Serious Side Effects with Breakthrough Cancer Pain Drug FDA Warns of Potential Serious Side Effects with Breakthrough Cancer Pain Drug The Food and Drug Administration is alerting health care professionals and consumers to concerns over the use of Read more... PRESS RELEASE: Cephalon Warns Doctors Over Pain Drug Deaths Says FDA Cephalon Warns Doctors Over Pain Drug Deaths Says FDA FRAZER, Pa., Sept. 13 -- Cephalon, Inc. today communicated with healthcare professionals to clarify the appropriate patient selection, dosing Read more... PRESS RELEASE: Cephalon Announces Agreement to Acquire AMRIX Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant FDA Approved Product Will Accelerate Growth of Pain Franchise FRAZER, Pa., Aug. 23 Read more... |
Get more Cephalon coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight